This article is a correction to:
Targeted Therapy in Cardiovascular Disease: A Precision Therapy Era
Mengda Xu
Kailun Zhang1*
Jiangping Song- 1Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- 2State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
A Corrigendum on
Targeted therapy in cardiovascular disease: A precision therapy era
by Xu M and Song J (2021). Front. Pharmacol. 12:623674. doi: 10.3389/fphar.2021.623674
In the published article, there was an error in Mengda Xu’s listed Affiliation. He is not affiliated with the “State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,” but rather only with “Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.”
In addition, there was an error in the author list, and corresponding author “Kailun Zhang” had not been included. The correct Author list, Affiliation list, and Correspondence information appear below:
“Mengda Xu1, Kailun Zhang1,* and Jiangping Song2,*”
“1Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China”
“*Correspondence: Kailun Zhang, whxxprofzhangkl@163.com; Jiangping Song, fwsongjiangping@126.com”
The Author contributions section has been revised to reflect this amendment:
“JS and KZ had the idea for the article. MX and JS participated in the literature retrieval. MX contributed to the writing of this review. JS and KZ provided critical appraisal and editorial assistance.”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: targeted therapy, antibody, gene editing, nucleic acid drugs, cell therapy, cardiovascular disease
Citation: Xu M, Zhang K and Song J (2023) Corrigendum: Targeted therapy in cardiovascular disease: A precision therapy era. Front. Pharmacol. 14:1145460. doi: 10.3389/fphar.2023.1145460
Received: 16 January 2023; Accepted: 23 January 2023;
Published: 03 February 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Xu, Zhang and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kailun Zhang, whxxprofzhangkl@163.com; Jiangping Song, fwsongjiangping@126.com